Alloy Therapeutics
Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.
Wheeler Bio
Series A in 2025
Wheeler Bio is a biomanufacturing company established in 2020 in Oklahoma City by Jesse McCool. The company focuses on accelerating the translation of therapeutic innovations into clinical applications through its biomanufacturing platform. By integrating pre-clinical discovery with biomanufacturing, Wheeler Bio aims to fill critical gaps between the discovery phase and early development. Its Portable CMC platform provides biopharma companies with rapid access to quality biomanufacturing, enabling a reliable pathway to clinical trials. This approach is designed to democratize access to comprehensive discovery-to-IND programs, making it easier for clients to navigate the complexities of bringing new therapies to market.
Wheeler Bio
Series A in 2022
Wheeler Bio is a biomanufacturing company established in 2020 in Oklahoma City by Jesse McCool. The company focuses on accelerating the translation of therapeutic innovations into clinical applications through its biomanufacturing platform. By integrating pre-clinical discovery with biomanufacturing, Wheeler Bio aims to fill critical gaps between the discovery phase and early development. Its Portable CMC platform provides biopharma companies with rapid access to quality biomanufacturing, enabling a reliable pathway to clinical trials. This approach is designed to democratize access to comprehensive discovery-to-IND programs, making it easier for clients to navigate the complexities of bringing new therapies to market.
Wheeler Bio
Seed Round in 2022
Wheeler Bio is a biomanufacturing company established in 2020 in Oklahoma City by Jesse McCool. The company focuses on accelerating the translation of therapeutic innovations into clinical applications through its biomanufacturing platform. By integrating pre-clinical discovery with biomanufacturing, Wheeler Bio aims to fill critical gaps between the discovery phase and early development. Its Portable CMC platform provides biopharma companies with rapid access to quality biomanufacturing, enabling a reliable pathway to clinical trials. This approach is designed to democratize access to comprehensive discovery-to-IND programs, making it easier for clients to navigate the complexities of bringing new therapies to market.
Wheeler Bio
Funding Round in 2021
Wheeler Bio is a biomanufacturing company established in 2020 in Oklahoma City by Jesse McCool. The company focuses on accelerating the translation of therapeutic innovations into clinical applications through its biomanufacturing platform. By integrating pre-clinical discovery with biomanufacturing, Wheeler Bio aims to fill critical gaps between the discovery phase and early development. Its Portable CMC platform provides biopharma companies with rapid access to quality biomanufacturing, enabling a reliable pathway to clinical trials. This approach is designed to democratize access to comprehensive discovery-to-IND programs, making it easier for clients to navigate the complexities of bringing new therapies to market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.